Covid-19

Successful repurposing of empagliflozin to treat neutropenia in a severe congenital neutropenia patient with G6PC3 mutations

Nov 24, 2024

EuNet-INNOCHRON Action’s achievements and impact

Nov 06, 2024

Final Conference of EUNet-INNOCHRON

Apr 18, 2024

Useful Links

COST

CA18233 Info

COST Documents and Guidelines

Social Media

We invite you to connect with EuNet-INNOCHRON on Social Media as follows

Want to find out more about EuNet-INNOCHRON?
Watch our promotional video!

Action's Chair

Prof Helen PAPADAKI
+302810394637
e.papadaki@uoc.gr

COST (European Cooperation in Science and Technology) is a funding agency for research and innovation networks. Our Actions help connect research initiatives across Europe and enable scientists to grow their ideas by sharing them with their peers. This boosts their research, career and innovation.

Main Menu

Recommendations regarding covid-19 infection

Expert opinions for specific non-malignant hematologic diseases

Successful repurposing of empagliflozin to treat neutropenia in a severe congenital neutropenia patient with G6PC3 mutations

EuNet-INNOCHRON Action’s achievements and impact

Final Conference of EUNet-INNOCHRON